Watch COCP. Know when insiders buy.
One email the day a filing lands. Free.
COCP
Cocrystal Pharma, Inc.
1.23
−0.01 −0.81%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $23.7MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$9.9MNET DEBT $42.9M52W 0.82 – 1.58SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $105K | — | — | −$3.2M | −$3.2M | — | -0.23 | −$2.5M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $225K | — | — | −$2.4M | −$2.3M | — | -0.17 | −$2.3M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.5M | −$2.4M | — | -0.17 | −$1.7M | $0 | −$1.7M | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$2.1M | −$2M | — | -0.19 | −$1.4M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$2.1M | −$2.1M | — | -0.20 | −$2.2M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$2.3M | −$2.3M | — | -0.23 | −$2.9M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$3.2M | −$3.3M | — | -0.32 | −$3.2M | $0 | −$3.2M | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$5M | −$4.9M | — | -0.49 | −$5.1M | $0 | −$5.1M | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$5.4M | −$5.3M | — | -0.53 | −$3.7M | $0 | −$3.7M | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$4.2M | −$4M | — | -0.39 | −$4.5M | $8K | −$4.5M | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$4.7M | −$4.5M | — | -0.44 | −$3.3M | $59K | −$3.4M | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$4.4M | −$4.2M | — | -0.41 | −$2.7M | $0 | −$2.7M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$9M | −$8.8M | — | -0.78 | −$8.2M | $12K | −$8.2M | — | — |
| FY2024 · to Dec 31 | — | — | −$17.9M | −$17.5M | — | -1.72 | −$16.5M | $8K | −$16.5M | — | — |
| FY2023 · to Dec 31 | — | — | −$18.6M | −$18M | — | -1.87 | −$14.7M | $118K | −$14.8M | — | — |
| FY2022 · to Dec 31 | — | — | −$38.8M | −$38.8M | — | -4.77 | −$21.4M | $74K | −$21.5M | — | — |
| FY2021 · to Dec 31 | — | — | −$14.2M | −$14.2M | — | -0.16 | −$12.7M | $52K | −$12.8M | — | — |
| FY2020 · to Dec 31 | $2M | — | −$9.6M | −$9.6M | -479.0% | -0.17 | −$9.8M | $240K | −$10.1M | — | — |
Every number comes from Cocrystal Pharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.